Journal of Viral Hepatitis最新文献_第6页

Cardiac MRI Identifies Subclinical Myocardial Tissue Abnormalities in Individuals With Hepatitis C Regardless of Myocardial Damage Markers or Fibrosis Stage 心脏MRI识别丙型肝炎患者的亚临床心肌组织异常，无论心肌损伤标志物或纤维化阶段如何。

IF 2.3 3区医学

Journal of Viral Hepatitis Pub Date : 2026-06-11 DOI: 10.1111/jvh.70197

Aaron D'Amore, Arlene Sirajuddin, Nivya George, Mark Ahlman, Jatin Raj Matta, Henry Masur, Shyamasundaran Kottilil, Ahmed M. Gharib, Poonam Mathur

引用次数: 0

Drug Use and Social Connectivity Related to Hepatitis C Infection Among Rural People Who Use Drugs 农村吸毒人群中与丙型肝炎感染相关的药物使用和社会连通性

IF 2.3 3区医学

Journal of Viral Hepatitis Pub Date : 2026-06-11 DOI: 10.1111/jvh.70200

Alex Rains, Ellen Almirol, William Nicholson, Scott Fletcher, Wiley D. Jenkins, John A. Schneider, Mai T. Pho

{"title":"Drug Use and Social Connectivity Related to Hepatitis C Infection Among Rural People Who Use Drugs","authors":"Alex Rains, Ellen Almirol, William Nicholson, Scott Fletcher, Wiley D. Jenkins, John A. Schneider, Mai T. Pho","doi":"10.1111/jvh.70200","DOIUrl":"10.1111/jvh.70200","url":null,"abstract":"People who use drugs (PWUD) have a disproportionately elevated risk of hepatitis C virus (HCV). Appropriate screening and treatment may be limited, especially in rural environments experiencing healthcare shortages. In order to develop targeted intervention strategies for rural PWUD, we investigated individual and network-level correlates of HCV positivity. Survey data were collected from PWUD from the Illinois region of the Federal Delta Regional Authority (DRA). The primary outcome of interest was HCV positivity by self-report. We explored associations between HCV positivity and individual demographic, drug use, and service utilisation characteristics as well as degree of connectedness within social networks. Three hundred and two participants were included in analyses. At the individual level, HCV positivity was associated with injection drug use, overdose history, and prior receipt of substance use treatment. Two hundred and one participants had at least one connection to a peer via referral chains, most of which contained a mix of HCV-negative and positive individuals. Of note, isolated individuals had comparable rates of HCV positivity compared to their socially connected peers. Degree of connectedness was not associated with HCV positivity. This study highlights the heterogeneity, both with respect to HCV positivity and other characteristics, among networks of rural PWUD. Given that most participants were connected to others, HCV interventions led by peer champions may facilitate improved access to critical services for risk mitigation.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 7","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70200","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148218269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genotypes of Hepatitis B and D Viruses Among Patients With Hepatitis D in the United States 美国丁型肝炎患者中乙型和丁型肝炎病毒的基因型

IF 2.3 3区医学

Journal of Viral Hepatitis Pub Date : 2026-06-04 DOI: 10.1111/jvh.70186

Andrew Lopez, Harish Gopalakrishna, Silvia Chang, Savrina Manhas, Nadine Peinovich, Christopher Richards, Grace Chee, Ross Martin, Roberto Mateo, Maria Mironova, Brooke E. Swanson, William A. Meyer III, Elizabeth M. Marlowe, Chunfeng Li, Hongmei Mo, Theo Heller, Evguenia Maiorova, Christopher Koh

{"title":"Genotypes of Hepatitis B and D Viruses Among Patients With Hepatitis D in the United States","authors":"Andrew Lopez, Harish Gopalakrishna, Silvia Chang, Savrina Manhas, Nadine Peinovich, Christopher Richards, Grace Chee, Ross Martin, Roberto Mateo, Maria Mironova, Brooke E. Swanson, William A. Meyer III, Elizabeth M. Marlowe, Chunfeng Li, Hongmei Mo, Theo Heller, Evguenia Maiorova, Christopher Koh","doi":"10.1111/jvh.70186","DOIUrl":"10.1111/jvh.70186","url":null,"abstract":"The epidemiological landscape of paired hepatitis B virus (HBV)/hepatitis delta virus (HDV) genotype (GT) among patients with HDV in the US remains unknown. HBV/HDV genotypes were assessed in two independent US cohorts: Cohort 1 included 5222 HBV-positive patients from Quest Diagnostics, including 114 anti-HDV+ patients; Cohort 2 included 178 anti-HDV+ samples from highly phenotyped patients managed at the National Institutes of Health (NIH). HBV/HDV sequencing and genotyping were analysed using phylogenetic analyses. In the overall cohort, HBV and HDV genotypes were determined for 197 (67%) and 139 (48%) patients, respectively, with HDV GT1 and GT5 and paired HBV/HDV genotypes D/1 and A/1 being the most prevalent. The most frequent HBV genotypes were GTD (40%) and GTA (35%), and the most frequent HDV genotypes were GT1 (84%) and GT5 (13%). Among 111 paired HBV/HDV genotypes, D/1 (50%) and A/1 (26%) were most common. In Cohort 2, 77 (79%) patients with HDV GT1 were foreign-born, most commonly Mongolian-born (47/77, 61%), while 21% (20/77) were US-born. Among patients with HDV GT5, GT6, or GT7, 93% (14/15) were of African origin. Overall, these findings provide the first comprehensive US analysis of HBV/HDV paired genotypes among patients with HDV and indicate that HBV genotype distributions differ between HBV/HDV coinfection and HBV monoinfection.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 7","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70186","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148157119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Host Factors DDB2 and DNA Polymerase Delta Are Linked to cccDNA Persistence in Hepatitis B Virus and Occult Hepatitis B Virus-Related Hepatocellular Carcinoma. 宿主因子DDB2和DNA聚合酶Delta与乙型肝炎病毒和隐性乙型肝炎病毒相关肝细胞癌中cccDNA持久性相关

IF 2.3 3区医学

Journal of Viral Hepatitis Pub Date : 2026-06-01 DOI: 10.1111/jvh.70182

Kanyakorn Singsung, Athaya Vorasittha, Pisit Tangkijvanich, Yasuhito Tanaka, Natthaya Chuaypen, Pongserath Sirichindakul

{"title":"Host Factors DDB2 and DNA Polymerase Delta Are Linked to cccDNA Persistence in Hepatitis B Virus and Occult Hepatitis B Virus-Related Hepatocellular Carcinoma.","authors":"Kanyakorn Singsung, Athaya Vorasittha, Pisit Tangkijvanich, Yasuhito Tanaka, Natthaya Chuaypen, Pongserath Sirichindakul","doi":"10.1111/jvh.70182","DOIUrl":"10.1111/jvh.70182","url":null,"abstract":"Covalently closed circular DNA (cccDNA), a stable episomal form of the hepatitis B virus (HBV) genome, functions as the transcriptional template for viral replication and persistence, posing a major barrier to HBV cure. While host DNA repair factors such as DDB2 and DNA polymerase delta (Pol δ) have been involved in cccDNA regulation in vitro, clinical validation remains limited. This study investigated the role of DDB2 and Pol δ in cccDNA maintenance using HBV-infected cell models and liver tissues from patients with HBV-related and occult HBV infection (OBI)-associated hepatocellular carcinoma (HCC). HepG2-NTCP cells infected with HBV were transfected with siRNAs targeting DDB2 or Pol δ, followed by quantification of intracellular cccDNA using droplet digital PCR (ddPCR). In liver tissues from HBV-HCC and OBI-HCC patients, the expression of DDB2 and Pol δ was assessed, while intrahepatic HBV DNA and cccDNA were measured by qPCR and ddPCR. Serum HBcrAg levels were evaluated using the iTACT-HBcrAg assay. Knockdown of DDB2 and Pol δ significantly reduced intracellular cccDNA levels (p = 0.010 and p = 0.006, respectively). In patient tissues, intrahepatic HBV DNA and cccDNA were markedly lower in OBI-HCC compared to HBV-HCC, despite comparable DDB2 and Pol δ expression. HBcrAg was detectable in 91.3% of HBV-HCC versus only 23.8% of OBI-HCC cases (p < 0.001). DDB2 expression correlated with intrahepatic viral markers in both groups and with HBcrAg only in HBV-HCC. These findings suggest that DDB2 is involved in cccDNA persistence and represents potential therapeutic targets for both overt and occult HBV-related HCC.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 6","pages":"e70182"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatitis B Surface Antigen Loss and Improved Clinical Outcomes in US Individuals With Chronic Hepatitis B Virus Infection. 美国慢性乙型肝炎病毒感染患者的乙型肝炎表面抗原丢失和改善的临床结果

IF 2.3 3区医学

Journal of Viral Hepatitis Pub Date : 2026-06-01 DOI: 10.1111/jvh.70184

Myriam Drysdale, Rose Chang, Shuang Wang, Anna Coutinho, Vera Gielen, Theo Man, Rui Song, Mei Sheng Duh, Mandana Khalili, Dickens Theodore

{"title":"Hepatitis B Surface Antigen Loss and Improved Clinical Outcomes in US Individuals With Chronic Hepatitis B Virus Infection.","authors":"Myriam Drysdale, Rose Chang, Shuang Wang, Anna Coutinho, Vera Gielen, Theo Man, Rui Song, Mei Sheng Duh, Mandana Khalili, Dickens Theodore","doi":"10.1111/jvh.70184","DOIUrl":"10.1111/jvh.70184","url":null,"abstract":"Hepatitis B surface antigen (HBsAg) loss is associated with improved clinical outcomes in patients with chronic hepatitis B virus (HBV) infection based on studies predominantly in Asian populations. We assessed real-world associations between HBsAg loss and long-term clinical outcomes in a diverse US population with chronic HBV infection. This retrospective cohort study (January 2012-December 2019) used Optum electronic health records data from patients with chronic HBV infection, identified via diagnosis codes or laboratory assessments. Patients with advanced liver disease and hepatitis C, hepatitis D or HIV co-infection at baseline were excluded. Associations between HBsAg loss, as a proxy of functional cure, and clinical outcomes were assessed using doubly robust inverse probability of treatment-weighted Cox proportional hazards models. In total, 15,760 patients with chronic HBV infection were included; 5.6% were receiving stable antiviral treatment. Overall, 4.2% (n = 667) experienced HBsAg loss across the study period. HBsAg loss was associated with an 89% and 62% reduced risk of hepatocellular carcinoma (HCC; adjusted hazard ratio [aHR]: 0.11, 95% CI: 0.01-0.76) and all-cause mortality (ACM; aHR: 0.38, 95% CI: 0.20-0.74), respectively. Risks of compensated cirrhosis (aHR: 0.84, 95% CI: 0.52-1.35) and decompensated liver disease (aHR: 0.74, 95% CI: 0.37-1.48) were lower after HBsAg loss, but did not reach significance. In this large, diverse population of patients with chronic HBV infection without advanced liver disease, HBsAg loss was associated with reduced risks of HCC and ACM compared with those without HBsAg loss.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 6","pages":"e70184"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13179525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147948680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness, Safety and Patient-Reported Outcomes of Bulevirtide Therapy in Chronic Hepatitis Delta: Real-World Evidence From a Prospective Observational Study. 布来韦肽治疗慢性丁型肝炎的有效性、安全性和患者报告的结果：来自前瞻性观察研究的真实世界证据。

IF 2.3 3区医学

Journal of Viral Hepatitis Pub Date : 2026-06-01 DOI: 10.1111/jvh.70181

Daniele Mengato, Sara Battistella, Alessandro Cadore, Elisabetta Mariavittoria Giunco, Paola Zanaga, Teresa Zappitelli, Antonietta Romano, Marta Tonon, Francesca Pasin, Francesco Barbaro, Lolita Sasset, Laura Scribano, Martina Gambato, Giacomo Berti, Paolo Simioni, Annamaria Cattelan, Patrizia Burra, Francesca Venturini, Francesco Paolo Russo

{"title":"Effectiveness, Safety and Patient-Reported Outcomes of Bulevirtide Therapy in Chronic Hepatitis Delta: Real-World Evidence From a Prospective Observational Study.","authors":"Daniele Mengato, Sara Battistella, Alessandro Cadore, Elisabetta Mariavittoria Giunco, Paola Zanaga, Teresa Zappitelli, Antonietta Romano, Marta Tonon, Francesca Pasin, Francesco Barbaro, Lolita Sasset, Laura Scribano, Martina Gambato, Giacomo Berti, Paolo Simioni, Annamaria Cattelan, Patrizia Burra, Francesca Venturini, Francesco Paolo Russo","doi":"10.1111/jvh.70181","DOIUrl":"10.1111/jvh.70181","url":null,"abstract":"Chronic hepatitis delta (CHD) is the most severe form of viral hepatitis and is associated with accelerated progression to cirrhosis and liver failure. Bulevirtide has shown promising results in trials, but real-world data on its effectiveness, safety and impact on patient-reported outcomes (PROs) remain limited. To evaluate the effectiveness, safety, and PROs (quality-of life-QoL; adherence) of bulevirtide therapy in CHD patients undergoing a dedicated pharmacist-led patient-education program (PEP). A prospective observational study enrolled 31 consecutive CHD patients receiving bulevirtide 2 mg daily at a tertiary referral centre. Virological, biochemical and combined responses were assessed at weeks 24, 48 and 60. QoL (through EQ-5D-5L questionnaire), adherence (proportion of days covered), and adverse events were monitored during follow-up. Bulevirtide significantly reduced HDV-RNA by week 24 (p < 0.01), with further reductions at week 48 (p = 0.05) and 60 (p < 0.01). Liver tests improved significantly from baseline to week 24 (p < 0.01) and remained stable. Combined response was achieved in 43.7% of patients by week 60. QoL improved significantly (p = 0.03), and adherence was excellent (≥ 90%). Adverse events were mostly mild and transient. In real-world clinical practice, bulevirtide achieved sustained virological and biochemical improvements with favourable safety and quality-of-life outcomes, confirming its effectiveness in routine management of CHD. While the 60-week data (n = 16) are exploratory due to the sample size, these findings confirm its effectiveness and safety in routine management of CHD.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 6","pages":"e70181"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147868820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Low-Barrier Fibrosis Screening in Hepatitis C Treatment: The Decompensated Cirrhosis in Hepatitis C Evaluation Questionnaire. 丙型肝炎治疗中的低屏障纤维化筛查：丙型肝炎失代偿肝硬化评估问卷。

IF 2.3 3区医学

Journal of Viral Hepatitis Pub Date : 2026-06-01 DOI: 10.1111/jvh.70180

Hunter Spencer, Barbara Brumbach, Anna Geduldig, Lisa Nelson, Andrew Seaman

{"title":"Low-Barrier Fibrosis Screening in Hepatitis C Treatment: The Decompensated Cirrhosis in Hepatitis C Evaluation Questionnaire.","authors":"Hunter Spencer, Barbara Brumbach, Anna Geduldig, Lisa Nelson, Andrew Seaman","doi":"10.1111/jvh.70180","DOIUrl":"10.1111/jvh.70180","url":null,"abstract":"Achieving hepatitis C virus (HCV) elimination requires innovative paradigms that overcome barriers to treatment, such as requiring pre-treatment elastography or phlebotomy-based fibrosis assessment. To identify patients at low risk of advanced fibrosis or decompensated cirrhosis within our HCV treatment programme, we developed and retrospectively assessed a clinical decision tool, the Decompensated Cirrhosis in Hepatitis C Evaluation Questionnaire (DCHEQ). Here we describe the development of DCHEQ and its test characteristics. We conducted a retrospective, nested, case-control study within a cohort of 1743 patients with HCV enrolled in an urban HCV elimination programme. The primary analysis defined cases of decompensated cirrhosis by chart review. A secondary analysis defined cases of advanced fibrosis as those with aspartate aminotransferase (AST)-platelet ratio index (APRI) > 1.5. The primary outcome was the area under the receiver operator curve (AUC) of the total DCHEQ to predict decompensated cirrhosis. We also compared the AUC of the total DCHEQ to the AUC of components of the DHEQ. For detecting cases of decompensated cirrhosis, the total of all DCHEQ items resulted in a mean AUC = 0.991 (95% CI = 0.963-1.000), which was significantly better than the discrimination of any alternative combination of DCHEQ items (p < 0.00001). For detecting cases of advanced fibrosis, the total DCHEQ score resulted in a mean AUC = 0.921 (95% CI = 0.871-0.966), which was superior to all other DCHEQ item combinations (p < 0.02). DCHEQ exhibited exquisite discrimination between cases of both decompensated cirrhosis and advanced fibrosis versus controls. After prospective validation, DCHEQ could be included in test-and-treat HCV treatment paradigms.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 6","pages":"e70180"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13125971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147775235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Course and Outcomes of Paediatric Chronic Hepatitis B: Insights From a Multicenter Longitudinal Cohort of 248 Patients. 儿科慢性乙型肝炎的临床过程和结局：来自248名患者的多中心纵向队列的见解。

IF 2.3 3区医学

Journal of Viral Hepatitis Pub Date : 2026-06-01 DOI: 10.1111/jvh.70183

Roberto Privato, Michele Pinon, Valentina Buccella, Mara Corpino, Angelo Di Giorgio, Simona Carrera, Chiara Rubino, Claudia Mandato, Massimo Luca Castellazzi, Sandra Trapani, Emanuele Nicastro, Giuseppe Indolfi

{"title":"Clinical Course and Outcomes of Paediatric Chronic Hepatitis B: Insights From a Multicenter Longitudinal Cohort of 248 Patients.","authors":"Roberto Privato, Michele Pinon, Valentina Buccella, Mara Corpino, Angelo Di Giorgio, Simona Carrera, Chiara Rubino, Claudia Mandato, Massimo Luca Castellazzi, Sandra Trapani, Emanuele Nicastro, Giuseppe Indolfi","doi":"10.1111/jvh.70183","DOIUrl":"10.1111/jvh.70183","url":null,"abstract":"Chronic hepatitis B virus (HBV) infection in children remains a dynamic condition with an incompletely defined natural history. We conducted a multicenter, retrospective cohort study across six Italian paediatric centers to characterize disease progression, evaluate the applicability of adult-derived classification systems, and identify predictors of HBeAg seroconversion. Children aged 0-18 years with chronic HBV diagnosed between January 2006 and August 2024 were included. The primary outcome was spontaneous HBeAg seroconversion, while secondary outcomes included the applicability of the 2017 EASL phase classification and the characterization of children requiring antiviral therapy. Of 248 children included, 45% were unclassifiable by 2017 EASL criteria at baseline. HBeAg seroconversion occurred in 129 children (52%): 34 (26%) were HBeAg-negative at baseline and 95 (74%) seroconverted during follow-up. Higher baseline ALT levels were significantly associated with seroconversion (p < 0.001), whereas HBV DNA levels were not. Seroconversion was less frequent among children of Asian origin (p < 0.001). Fourteen children (6%) received antiviral therapy with 50% achieving seroconversion; all treatments were well tolerated. Applying 2024 WHO guidelines retrospectively, 81 children (33%) would have met treatment criteria. Despite this, most children were not treated, reflecting a cautious clinical approach that may be justified by the high rates of spontaneous viral control. These findings underscore the limitations of adult-derived classification systems in paediatric populations and highlight the need for paediatric-specific management frameworks and prospective studies to optimize treatment strategies.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 6","pages":"e70183"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147874595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interventions to Increase Hepatitis B Testing Uptake Amongst Detained Populations: A Systematic Review. 在拘留人群中增加乙肝检测的干预措施：一项系统综述。

IF 2.3 3区医学

Journal of Viral Hepatitis Pub Date : 2026-06-01 DOI: 10.1111/jvh.70189

Saumiya M Kesavan, Ghulam Khan, Kathryn Jack, Elisa Martello, Joanne R Morling, Jo Leonardi-Bee

{"title":"Interventions to Increase Hepatitis B Testing Uptake Amongst Detained Populations: A Systematic Review.","authors":"Saumiya M Kesavan, Ghulam Khan, Kathryn Jack, Elisa Martello, Joanne R Morling, Jo Leonardi-Bee","doi":"10.1111/jvh.70189","DOIUrl":"10.1111/jvh.70189","url":null,"abstract":"People who have been detained have a higher prevalence of hepatitis B virus (HBV) than the general population, yet testing uptake remains limited. Improving testing uptake in high-risk settings is essential to the World Health Organization 2030 elimination target. This systematic review examines interventions aimed at increasing hepatitis B testing uptake in prison. MEDLINE, EMBASE, CENTRAL and CINAHL were searched from January 2000 to April 2025. Quantitative interventional studies were included. Quality appraisal was conducted using the JBI critical appraisal tool. A random effects meta-analysis with Freeman-Tukey transformation estimated testing uptake. Subgroup analysis explored heterogeneity by sex, geographical region and the screening approach. Sixteen papers (15 studies) were included. Eleven were post-interventional quasi-experimental studies. Nine were conducted in Europe. The pooled testing uptake was 64% (95% CI 46%-80%; I2 = 98%). Opt-in interventions were associated with a higher testing uptake (77%, 95% CI 59%-91%), in comparison to opt-out testing uptake (33%, 95% CI 17%-52%; p < 0.001), although opt-in screening had enhanced characteristics such as counselling, peer education and culturally tailored approaches. HBV prevalence amongst institutions ranged between 0% and 11.4%. Only one study reports costs. Opt-in programmes were associated with a higher testing uptake in comparison to opt-out programmes, which may reflect the underlying programme characteristics rather than the screening approach alone. Evidence on cost-effectiveness is limited. Most studies were heterogeneous and conducted in high-income countries. Further robust studies are needed to evaluate enhanced screening approaches to determine the most effective and scalable screening programme.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 6","pages":"e70189"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147982360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence of HIV and HCV Among People Who Inject Drugs in Montreal, Canada: Data From the HEPCO Longitudinal Cohort Study, 2011-2025. 加拿大蒙特利尔注射吸毒者中HIV和HCV的发病率：来自HEPCO纵向队列研究的数据，2011-2025

IF 2.3 3区医学

Journal of Viral Hepatitis Pub Date : 2026-06-01 DOI: 10.1111/jvh.70185

Bluma Blake Kleiner, Milca Meconnen, Marleine Azar, Nanor Minoyan, Geng Zang, Adelina Artenie, Valérie Martel-Laferrière, Didier Jutras-Aswad, Julie Bruneau, Sarah Larney

{"title":"Incidence of HIV and HCV Among People Who Inject Drugs in Montreal, Canada: Data From the HEPCO Longitudinal Cohort Study, 2011-2025.","authors":"Bluma Blake Kleiner, Milca Meconnen, Marleine Azar, Nanor Minoyan, Geng Zang, Adelina Artenie, Valérie Martel-Laferrière, Didier Jutras-Aswad, Julie Bruneau, Sarah Larney","doi":"10.1111/jvh.70185","DOIUrl":"10.1111/jvh.70185","url":null,"abstract":"Ongoing monitoring of hepatitis C virus (HCV) and HIV incidence among people who inject drugs (PWID) is important for epidemic control and assessing progress towards disease elimination. We estimated trends in HIV and HCV infection incidence in a community-based cohort of PWID in Montreal, Canada. Data from March 2011 to March 2025 were drawn from the HEPCO study of PWID aged ≥ 18 years and living in Montreal. Participants with at least two visits were included in analyses. We used a random point approach to estimate the date of each infection event, imputing each date 1000 times, and Rubin's rules to pool incidence rates and 95% CIs across imputations. A total of 743 participants contributed to HCV analyses, with 152 infection events and incidence of 6.47 per 100 person-years (p-y) (95% CI 6.46-6.49). Incidence peaked in 2013 and declined to 2019 before increasing again post-pandemic. There were 61 primary HCV infection events (incidence: 6.15 per 100 p-y; 95% CI 4.79-7.90) and 91 reinfection events (incidence: 6.71 per 100 p-y; 95% CI 6.69-6.73). A total of 836 participants contributed to HIV analysis, with only eight infections over 3089.89 p-y (incidence: 0.26 per 100 p-y; 95% CI 0.13-0.52). Declining HCV incidence among PWID in Montreal may have reversed, but limited data collection during the years 2020-2021 complicates interpretation. HIV incidence was persistently low. HCV incidence remains above World Health Organization elimination targets, highlighting the need for sustained investment in prevention and linkage to care for PWID.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 6","pages":"e70185"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13179476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147948687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0